GSA Capital Partners LLP Purchases Shares of 8,100 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

GSA Capital Partners LLP purchased a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 8,100 shares of the biotechnology company’s stock, valued at approximately $291,000.

Other large investors also recently bought and sold shares of the company. GAM Holding AG acquired a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at approximately $108,000. Mason Street Advisors LLC increased its holdings in shares of Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 212 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its holdings in shares of Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 110 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 237 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its holdings in shares of Enanta Pharmaceuticals by 62.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,702 shares during the last quarter. 66.24% of the stock is owned by hedge funds and other institutional investors.

Several research firms have issued reports on ENTA. BidaskClub cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Royal Bank Of Canada began coverage on Enanta Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating for the company. JMP Securities raised Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price for the company in a research note on Tuesday, July 11th. Zacks Investment Research cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and set a $38.00 price target (up from $32.00) on shares of Enanta Pharmaceuticals in a research report on Wednesday, August 9th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Enanta Pharmaceuticals has a consensus rating of “Buy” and an average price target of $45.25.

WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/27/8100-shares-in-enanta-pharmaceuticals-inc-enta-purchased-by-gsa-capital-partners-llp.html.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) opened at 48.11 on Friday. Enanta Pharmaceuticals, Inc. has a 12-month low of $22.17 and a 12-month high of $49.50. The company has a 50-day moving average price of $46.02 and a 200-day moving average price of $37.87. The stock’s market capitalization is $918.42 million.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.05. The firm had revenue of $7.51 million for the quarter, compared to analyst estimates of $8.08 million. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The company’s revenue for the quarter was down 46.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.06) earnings per share. On average, equities research analysts forecast that Enanta Pharmaceuticals, Inc. will post $1.14 earnings per share for the current year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply